Rafferty Asset Management
AVBP icon

Rafferty Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Rafferty Asset Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$859K Buy
37,253
+8,375
+29% +$189K ﹤0.01% 808
2025
Q4 		$581K Sell
28,878
-5,483
-16% -$114K ﹤0.01% 884
2025
Q3 		$634K Buy
34,361
+18,612
+118% +$366K ﹤0.01% 870
2025
Q2 		$343K Sell
15,749
-1,660
-10% -$34.5K ﹤0.01% 955
2025
Q1 		$322K Sell
17,409
-9,890
-36% -$242K ﹤0.01% 946
2024
Q4 		$727K Buy
27,299
+17,763
+186% +$510K ﹤0.01% 847
2024
Q3 		$224K Buy
+9,536
New +$216K ﹤0.01% 1083

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Rafferty Asset Management's AVBP Position: Q1 2026 in Review

Rafferty Asset Management increased its ArriVent BioPharma (AVBP) stake by 29% in Q1 2026, buying an estimated $189K and bringing the position to 37,253 shares worth $859K. The position accounts for ﹤0.01% of the portfolio, ranked #808.

Rafferty Asset Management first reported a position in AVBP in Q3 2024 and has held it in 7 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Rafferty Asset Management held 37,253 shares of ArriVent BioPharma worth $859K as of Q1 2026.
  • Rafferty Asset Management bought 8,375 ArriVent BioPharma shares in Q1 2026, an estimated $189K.
  • ArriVent BioPharma made up ﹤0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #808 holding.
  • Rafferty Asset Management first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 7 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.